XGEVA 120 mg solution for injection

DRUG2 trials

Sponsors

Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group, Institut Catala D'oncologia, ANZ Breast Cancer Trials Group Limited, University Of Manchester, Alliance Foundation Trials LLC, Shaare Zedek Medical Center, Associazione Italiana Ematologia Oncologia Pediatrica

Conditions

Patients with Metastatic OsteosarcomaPrevention of breast cancer in women with a BRCA1 germline mutation

Phase 2

Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma

RecruitingCTIS2024-518167-35-01

Associazione Italiana Ematologia Oncologia PediatricaPatients with Metastatic Osteosarcoma

Start: 2025-12-19Target: 88Updated: 2025-08-07

Phase 3

BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation

RecruitingCTIS2024-513734-38-00

Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group, Institut Catala D'oncologia, ANZ Breast Cancer Trials Group Limited, University Of Manchester, Alliance Foundation Trials LLC, Shaare Zedek Medical CenterPrevention of breast cancer in women with a BRCA1 germline mutation

Start: 2019-07-03Target: 1150Updated: 2025-07-24